NEW YORK (GenomeWeb) – Ventana Medical Systems today said that it will collaborate with Merck KGaA on a companion diagnostic test for an undisclosed therapeutic target.
According to the firms, Ventana will develop and validate the CDx test for future clinical studies. Further details of the collaboration were not disclosed.
Tucson, Ariz.-based Ventana, which is part of the Roche Group, has several collaborations with biopharmaceutical firms to develop companion diagnostic products. Among its other partners are Bayer, Pfizer, Boehringer Ingelheim, and Takeda's Millennium unit. Last week it announced a deal to develop a companion diagnostic for a MedImmune drug in development for non-small cell lung cancer.